IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free report) – Equity research analysts at Leerink Partnrs lowered their third-quarter 2024 EPS estimates for IDEAYA Biosciences in a report released on Tuesday, October 22. Leerink Partnrs analyst A. Berens now expects the company to post earnings per share of ($0.71) for the quarter, down from his previous forecast of ($0.70). The consensus estimate for IDEAYA Biosciences’ current annual earnings is ($2.48) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences’ fourth quarter 2024 earnings at ($0.71) per share, fiscal 2024 earnings at ($2.64) per share, earnings for the FY 2025 earnings at ($3.28) per share, FY 2026 earnings at ($3.27) per share, FY 2027 earnings at ($2.54) per share and FY 2025 earnings at ($2.54) per share FY2028 at ($0.21) EPS.

IDEAYA Biosciences (NASDAQ:IDYA – Get a free report) last released its quarterly results on Tuesday, August 6. The company reported EPS of ($0.68) for the quarter, missing the consensus estimate of ($0.54) by ($0.14). During the same period of the previous year, the company posted earnings per share ($0.50).

Several other research analysts have also recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Stifel Nicolaus increased their price target on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. Oppenheimer lowered their price target on IDEAYA Biosciences from $60.00 to $53.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Lifesci Capital upgraded shares of IDEAYA Biosciences to a “strong buy” rating in a report on Monday, July 29. Finally, Mizuho covered IDEAYA Biosciences in a research report on Monday, July 8th. They set an “outperform” rating and a $50.00 price target for the company. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Buy” and an average target price of $55.45.

Check out our latest stock report on IDYA

IDEAYA Biosciences Stock Up 0.3%

Actions of IDEAYA Biosciences shares opened at $29.30 Thursday. IDEAYA Biosciences has a one-year low of $25.22 and a one-year high of $47.74. The company’s 50-day simple moving average is $34.32 and its two-hundred-day simple moving average is $37.54.

Institutional investors weigh in on IDEAYA Biosciences

Institutional investors and hedge funds have recently changed their positions in the company. Allworth Financial LP increased its stake in IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 800 shares during the last quarter. Quest Partners LLC purchased a new stake in IDEAYA Biosciences in the second quarter worth approximately $41,000. Covestor Ltd increased its position in IDEAYA Biosciences by 9,225.0% during the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after purchasing an additional 1,107 shares during the last quarter. Comerica Bank increased its stake in IDEAYA Biosciences by 723.5% during the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after acquiring an additional 1,324 shares during the period. Finally, JTC Employer Solutions Trustee Ltd purchased a new stake in shares of IDEAYA Biosciences during the 1st quarter valued at approximately $67,000. Institutional investors own 98.29% of the company’s shares.

IDEAYA Biosciences Company Profile

(Get a free report)

IDEAYA Biosciences, Inc, a precision medicine oncology company focused on synthetic lethality, discovers and develops targeted therapies for selected patient populations using molecular diagnostics in the United States. The Company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers with mutations in the GNAQ or GNA11 gene; IDE397, a methionine adenosyltransferase 2a inhibitor in Phase 1/2 clinical trials for patients with solid tumors with deletions of the methylthioadenosine phosphorylase gene, such as non-small cell cancers of the lung, bladder, stomach and esophagus; IDE161, a poly ADP-ribose glycohydrolase inhibitor currently in phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD) and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in phase 1 clinical trials for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Featured Stories

Receive daily news and reviews for IDEAYA Biosciences – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for IDEAYA Biosciences and related companies with MarketBeat.com’s FREE daily newsletter.